SpyGlass Pharma to Participate in Upcoming Investor Conferences

About this update from Spyglass Pharma, Inc.

[{"type":"image","alt":"SpyGlass Pharma, Inc.","displaySize":"","headline":null,"caption":"SpyGlass Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":90,"url":"https://media.zenfs.com/en/globenewswire.com/dc6caa52a627a0de62c10cbc13438f42"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8QpzLzFrLLjLv9v2aHJzmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNg--/https://media.zenfs.com/en/globenewswire.com/dc6caa52a627a0de62c10cbc13438f42","width":300,"height":90},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/8QpzLzFrLLjLv9v2aHJzmw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNg--/https://media.zenfs.com/en/globenewswire.com/dc6caa52a627a0de62c10cbc13438f42","width":300,"height":90}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences:","length":281,"tagName":"p"},{"type":"text","content":"Stifel 2026 Virtual Ophthalmology ForumDate: Tuesday, May 26, 2026Time: 2:00 p.m. ETFormat: Fireside Chat","length":108,"tagName":"p"},{"type":"text","content":"Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Time: 2:35 p.m. ETFormat: Fireside Chat","length":108,"tagName":"p"},{"type":"text","content":"Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Time: 10:40 a.m. ETFormat: Corporate Presentation","length":136,"tagName":"p"},{"type":"text","content":"A live webcast and subsequent replay of each presentation can be accessed via the Investor Relations section of the Company website at www.spyglasspharma.com.","length":158,"tagName":"p"},{"type":"text","content":"About SpyGlass Pharma","length":21,"tagName":"p"},{"type":"text","content":"SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company’s mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.","leng...

More updates from Spyglass Pharma, Inc.